Cooperative Health Research in the Augsburg Region

https://neurodegenerationresearch.eu/survey/cooperative-health-research-in-the-augsburg-region/

Title of cohort

Cooperative Health Research in the Augsburg Region

Acronym for cohort

KORA

Name of Principal Investigator - Title

Prof

Name of Principal Investigator - First name

Erich

Name of Principal Investigator - Last name

Wichmann

Address of institution -Institution

Helmholtz Zentrum München, German Research Center for Environmental Health

Address of institution - Street address

Ingolstädter Landstr. 1

Address of institution - City

Neuherberg

Address of institution - Postcode

85764

Country

Germany

Website

http://www.helmholtz-muenchen.de/en/kora-en/kora-homepage/index.html

Contact email

wichmann@helmholtz-muenchen.de

Funding source

Q1a. Please indicate below if your cohort includes or expects to include, incidence of the following conditions?

Neurodegenerative disease in general| Alzheimer's disease and other dementias| Parkinson's disease

Q1b. When are studies on the above condition(s) expected to become possible?

Already possible

Q2a. In a single sentence what is the stated aim of the cohort?

The aim of the cohort is to study behavioural, environmental and genetic risk factors for chronic diseases in the aging population and to study the role of subclinical intermediate phenotypes for disease development.

Q2b. What distinguishes this cohort from other population cohorts?

This is a population-based cohort and therefore will contain some persons with these disease. However, these patients are not identified by a clinical diagnosis but at best by a screening test

Q3a. i) Number of publications that involve use of your cohort to date

0

Q3a.ii) Please give up to three examples of studies to date (Principal Investigator, Institution, Title of Study)
Q3b. If data on research outputs are already available please paste the publication list/other data or provide a link to where these data are publicly available
Q3c. If no research has been done as yet, please explain in a few sentences what information (i.e. research findings) you expect will be gained from the population
Q4a. Study criteria: what is the age range of participants at recruitment? Age in years From:

25

Q4a. Study criteria: what is the age range of participants at recruitment? To:

until death

Q4b. Study criteria: what are the inclusion criteria?

only residents of the Augsburg region (> 600,000 inhabitants), German nationality

Q4c. Study criteria: what are the exclusion criteria?

unable to communicate in German, too ill to participate in study examination

Q5. What is the size of the cohort (i.e. how many participants have enrolled)?

More than 15,000 participants

Q6a. Please describe what measures are used to characterise participants

please check the KORA website. We have an extensive phenotypic characterization (examinations, interview, questionnaires) including hundreds of variables. In addition, we have blood samples and other biomaterials from which genetic and metabolomic markers have been measured.

Q6b. Are there additional measures for participants with a clinical disorder?
Q6c. Are there defined primary and secondary endpoints (e.g. defined health parameters)?
If yes please specify
Q7. What is the study design (select all that apply)?

Prospective cohort

Q8. Are your cases matched by
Q9a. Does your study include a specialised subset of control participants?

No

Q9b. If your study includes a specialised subset of control participants please describe

see Q8. Since all participants are selected from the population, they have several times been used as population controls.

Q10a. i) Please enter the data collection start date

01/01/1984

Q10a. ii) Please enter the data collection end date
Q10a. iii) Is data collection for this study

Data collection ongoing

Q10b. If data collection is ongoing, are there plans to continue the cohort study beyond the current projected end date?

Yes - intend to apply for funding

Q11. Is data collected
Other please specify here
Q12. Is there a system in place to enable re-contact with patients to ask about participation in future studies?
Q13a. Please give information on the format and availability of data stored in a database (1)

% available

Q13a. Please give information on the format and availability of data stored in a database (2)

% available

Q13a. Please give information on the format and availability of data stored in a database (3)

% available

Q13a. Please give information on the format and availability of data stored in a database (4)

% available

Other (please specify)

% available

Q13b. Please give information on the format and availability of data held as individual records (1)

% available

Q13b. Please give information on the format and availability of data held as individual records (2)

% available

Q13b. Please give information on the format and availability of data held as individual records (3)

% available

Q13b. Please give information on the format and availability of data held as individual records (4)

% available

Please specify language used

Q14a. Is data available to other groups?

Yes

Q14b. If data is available to other groups what is the access policy/mechanisms for access?

Q15. What data sharing policy is specified as a condition of use?

Data made publicly available after a specified time point

Q16a. Are tissues/samples/DNA available to other groups?

Yes

Q16b i) If yes, please describe below:

Q16b. ii) In what form are tissues/samples/DNA supplied?

Q16b. iii) Is the access policy/mechanism for obtaining samples the same as that for obtaining data (Q14 above)?

Q17. Is information on biological characteristics available to other groups?

Number of Patients

% of total cohort

Types:

Population Cohorts

Member States:

Germany

Diseases:

Alzheimer's disease & other dementias, Neurodegenerative disease in general, Parkinson's disease & PD-related disorders

Years:

2016

Database Categories:

N/A

Database Tags:

N/A